Marvel Biosciences Corp. has received approval from the TSX Venture Exchange to extend the closing deadline for its private placement from August 31 to September 14, 2026. The company, which develops synthetic chemical derivatives of off-patent drugs targeting neurological and other diseases, keeps all other terms of the offering unchanged. This extension allows Marvel more time to finalize the financing needed to advance its drug redevelopment projects. Investors can expect continued focus on neurological diseases and cancer as Marvel expands its pipeline.
Arm Holdings has introduced ready-made chip blueprints and a finished AGI CPU that offer hyperscalers a shortcut, potentially reducing demand for Marvell's custom chip designs. Arm's AGI CPU demand exceeds $2 billion, though supply constraints limit ...
Shares of major chipmakers like Marvell, AMD, and Intel dropped sharply after Lam Research, a chip equipment supplier, warned of ongoing supply chain constraints that could limit semiconductor production into 2027. This supply squeeze is hitting comp...
Credo Technology's stock has dropped 23.39% over three months despite delivering a strong quarter with 114.7% revenue growth and beating earnings estimates. The selloff followed concerns over margin contraction and customer concentration after a majo...
The AI investment trend is moving beyond GPU makers to focus on custom silicon, optical connectivity, and edge devices, benefiting chipmakers Marvell, Intel, and Qualcomm. Marvell, with strong data center revenue growth and custom silicon deals, coul...
Hedge funds sold technology stocks at the fastest rate in over ten years during the week ending October 15, 2026, with semiconductor stocks taking the biggest hit. This selling was primarily long liquidation, meaning funds sold shares they already ow...
